Vasculogenic mimicry (VM) refers to the unique capability of aggressive tumor cells to mimic the pattern of embryonic vasculogenic networks. In the study we demonstrated that CD133 expression was the highest in triple-negative (TN) breast cancer specimens. Importantly, VM showed statistical correlation with CD133 þ expression. The presence of the close relationship between VM and CD133 þ expression might be central for TN tumor relapse and progression. The TN breast cancer cell line, MDA-MB-231 cells developed a range of colony morphologies paralleling the holoclone, meroclone and paraclone morphologies produced by normal keratinocytes and other epithelial cancer cell lines when plated at clonal densities. Holoclone cells were capable of forming more colonies on soft agar than meroclone cells and paraclone cells, suggesting that holoclone cells had higher self-renew potential and might harbors cancer stem cells (CSCs) subpopulation. Strikingly, it was holoclone that displayed CD133 þ phenotype and formed VM. In addition, holoclone acquired endothelial cell marker vascular endothelialcadherin expression and upregulated VM mediators matrix metalloproteinase (MMP)-2 and MMP-9 expression. The subpopulation with holoclone morphology, CD133
INTRODUCTION
Cancer stem cells (CSCs) have been highlighted lately, because of the opinion that these CSCs are the culprits for therapeutic resistance, metastasis and recurrence of the tumors, and therefore, might be selected as the target of treatment. The cell surface markers CD44
þ /CD24 À were previously described as breast CSCs markers based on mouse model. 1 However, CD44 þ /CD24 À phenotype is not the universal marker for breast CSCs. Heterogeneity of cancer stem/progenitor cells that give rise to different forms of cancer had been well demonstrated in human tumors. CD133, also known as prominin-1, is a pentaspan transmembrane glycoprotein that localizes to membrane protrusions such as microvilli and in the apical surface of some epithelial cells. Expression of CD133 in cancer-initiating cells has been reported in several tumor types including hematopoietic malignancies and solid tumors such as retinoblastoma, glioblastomas, prostatic adenocarcinomas and kidney carcinomas. 2 --5 CD133 was recently identified for breast CSCs in cancer cell lines generated from Brca1 þ /À tumor had stem cell characteristics, including the ability to form spheroids, expression of stem cell genes and in vivo reconstitution of tumors with as few as 100 cells. 6 Growth, proliferation and metastasis of tumor have been thought to be dependent on the establishment of tumor vascular network, which provides nutrients required for cancer cell expansion and drains away wastes produced by cancer cells. Recent studies have suggested that tumor cells might be the progenitor for tumor vasculature. 7, 8 Endothelial cells could form blood vessels, which were called angiogenesis. However, a nonangiogenesis-dependent pathway, in which tumors can feed themselves, has also been reported. The process by which a vessel is formed from tumor cells is called vasculogenic mimicry (VM). 9, 10 It means the unique ability of aggressive tumor cells to express an endothelial phenotype and to form vessel-like networks, 'mimicking' the pattern of embryonic vascular networks. The patterned microcirculation characteristic of VM was first described in uveal (intraocular) melanoma. In addition, VM had been found in several other aggressive tumor types, including hepatocellular carcinoma, breast, prostate and ovarian carcinoma, and may serve as an important target for new cancer therapies. 11, 12 It is well known that tissue resident stem cells, such as neural, muscle and skin stem cells, were shown to differentiate into endothelial cells, which was called transdifferentiation and to participate in normal tissue vascularization after damage, thus providing a regenerative response. Just as normal stem cells have the transdifferentiation ability, so do CSCs. The research in melanoma, glioma and renal carcinomas showed that CSCs can transdifferentiate into different phenotype, they express angiogenic and vasculogenic markers and they are able to organize pseudovascular network. 13 --16 Breast cancer may be viewed as tissue consisting of a heterogeneous population of tumor cells that differ in molecular and biological characteristics. 17 Triplenegative (TN) breast cancer represents a unique subgroup, with a specific molecular profile, an aggressive behavior pattern, a relative lack of effective therapies and a poor prognosis. The relationship of CSCs and VM in TN breast cancer is currently unknown. In this study, we try to identify the potential contribution of CD133 þ CSCs to tumor vasculogenesis and thus provide novel therapeutic strategies for TN breast cancer. TN breast cancer specimens  by immunohistochemistry  Based on the criteria Immervoll H and Yeh CT  18,19 established with minor modification, two distinct CD133 staining patterns were observed. The first pattern was observed in the cancer cells that formed tubular structures. Breast cancer cells arranged in tubular structure showed apical/endoluminal cell surface CD133 staining (Figure 1a) . The second pattern was the abundant cytoplasmic and membrane positivity of CD133 staining (Figure 1b) or CD133 was mostly accumulated as patches with granular appearance in the cytoplasm (Figure 1c ). The percentage of CD133 þ cells in the total tumor cells ranged from 5 to 24% in the positive case. The clinicopathological data in patients with CD133 expression were compared with those without CD133 expression (Table 1) . Among all factors compared, the presence of nodal status and differentiation grade was significantly different (Po0.05) and the difference was independent of other factors. Lymph nodes metastasis and higher histological grade were correlated to CD133 expression.
RESULTS

CD133 expression was the highest in
According to the molecular classification described by Perou CM, 20 immunohistochemical profiles (human epidermal growth factor receptor 2-positive (HER2 þ )/hormone receptor (estrogen receptor a (ERa) and progestin receptor (PR))-negative for HER2 (Figure 2f ). There were significant differences among the three subtypes (F ¼ 17.446, P ¼ 0.000). By t-tests, no statistical difference was found between luminal and HER2 þ (t ¼ 0.674, P ¼ 0.502). But there was difference between TN and luminal (t ¼ 4.729, P ¼ 0.000), TN and HER2 þ (t ¼ 4.094, P ¼ 0.000). Therefore, the presence of VM was closely associated with TN breast cancer.
CD133
þ phenotype was positively associated with VM in breast cancer specimens We found the existence of PAS-positive tubular structures containing red blood cells but lined by CD31 negative cells in the luminal surface. They varied morphologically from large to small channels. By immunohistochemistry, our results showed that phenotype, which had been used to identify breast CSC population. However, different from CD44 þ /CD24 À/low phenotype, our studies showed that the size of CD133 þ population was found to be 25.4% in MDA-MB-231 cell line (Figure 4b ).
MDA-MB-231 cell holoclones, meroclones and paraclones; holoclone cells had a stronger self-renewal capacity in vitro MDA-MB-231 cells were plated under dilute conditions (B1 cell per well of 96-well plates) in regular medium and 54 clones with different morphologies were observed. These clones showed a spectrum of colony morphologies ranging from round or oval colonies of closely packed cells to irregularly shaped colonies consisting of loosely packed cells. Similar to clones observed in keratinocyte clones and prostate cancer cell clones when plated at clonal densities, 21, 22 three morphologically distinct colonies was observed after 6 --7 days of culture: holoclones, meroclones and paraclones (Figure 5a ). Holoclones were round or oval in shape, and the cells comprising them were tightly packed. Paraclones were irregular in shape and comprized of loosely packed cells, whereas the morphology of meroclones was intermediate to that of holoclones and paraclones. The parental MDA-MB-231 cell line yielded 13 (24.1%) holoclones, 19 (35.2%) meroclones and 22 (40.7%) paraclones (Figure 5b ) in the formed 54 clones. These morphologies were identifiable at the earliest stages of colony formation and were maintained as colonies increased in size.
In order to determine whether holoclone cells have the stem cell-like proliferative potential, we trypsinized holoclone cells, meroclone cells and paraclone cells and then subjected to soft agar colony formation assays. The colonies were scored to determine the colony forming efficiency (CFE) after culture. Our studies showed that holoclone cells exhibited higher clone forming ability and formed more colonies than meroclone cells and paraclone cells (Figure 5c ). The holoclone cells had a CFE of 14.4 ± 4% and meroclone cells had a CFE of 5.3 ± 1.7%, but the paraclone cells had a lower CFE of 1.5 ± 0.9% (P ¼ 0.000; Figure 5d ). The holoclone cells showed approximately threefold and tenfold increase in CFE when compared with that of meroclone cells and paraclone cells, respectively, suggesting that holoclone cells have a higher proliferative potential than meroclone and paraclone cells although they came from the same bulk population of MDA-MB-231 cells. The holoclones may contain CSCs subpopulation of MDA-MB-231 cell line. 
A greater CD133
þ population in holoclones than in paraclones and meroclones Immunofluorescence analysis was carried out to characterize CD133 expression in 7 holoclones, 10 meroclones and 6 paraclones, which was selected randomly. CD133 protein was mostly accumulated as patches with granular appearance in the cytoplasm according to literature 18 ( Figure 6a ). Our results indicated that CD133 expression was significantly different among the three clones. CD133 showed a consistent pattern of upregulated expression in holoclones when compared with paraclones and meroclones. The positive rate of CD133 expression ranged from 94 to 97.6% in holoclones, 1.7 to 13.7% in meroclones whereas all the paraclones didn't show CD133 expression (Figure 6b , P ¼ 0.000). These immunostaining results provide direct experimental evidence that MDA-MB-231 cell holoclones, but not meroclones and paraclones, contain stemlike cells.
The holoclone cells with the highest CD133 expression were trypsinized and cultured in a regular culture system. Flowcytometry analysis in 48 h showed that the prevalence of CD133 þ cells in holoclone cells decreased from 97.6 to 53.5% (Figure 6c) . With an additional two passages, the prevalence of this population decreased to 25.4% (Figure 6c ) and the prevalence of CD133 À subpopulations increased. Thus, after four passages, the proportion of CD133 þ and CD133 À subpopulation had already returned to that of the bulk population.
Holoclone cells were more potent in vascular channel formation and expressed endothelial cell marker vascular endothelial (VE)-cadherin The vasculogenic capacity in holoclone cells, meroclone cells and paraclone cells was compared. There was significant difference for the three clones in the efficiency of network formation. In the selected six holoclones, nine meroclones and nine paraclones, all the holoclones formed typical pipe-like structures whereas there was a lack of tube formation in meroclone and paraclone cells (Figure 7a The demonstration that holoclone cells could form vessel-like structures within Matrigel suggested that they may have the capacity to undergo differentiation into endothelial cells. To show conclusively that holoclone cells were able to acquire an endothelial cell phenotype upon differentiation, three clone cells were trypsinized and grown in coverslip under conditioned medium. Our studies showed that holoclone cell acquire endothelial cell marker VE-cadherin expression, whereas another major endothelial marker CD31 was lacking (Figure 7b ). However, neither meroclone nor paraclone showed detectable VE-cadherin or CD31 expression (Figure 7b ). The expression of VE-cadherin in holoclones suggested that holoclone cells had the capacity of transdifferentiation to differentiate into endothelial cells and acquire endothelial cell phenotype.
Matrix metalloproteinases (MMPs) protein was upregulated in holoclone than meroclone, paraclone and parental cells MMPs have been implicated in a variety of mechanisms that promote tumor progression and angiogenesis. Specifically, MMP-9 and MMP-2 are critical in cell plasticity and VM formation. 9 Tumor cells lining the VM networks can produce MMPs to induce extracellular matrix remodeling, thus promoting the formation of VM. Therefore, MMPs were identified as important mediators of VM. To determine whether the differential capacity of vascular channel formation in holoclone, meroclone and paraclone was associated with differential activation of MMPs, we went on to perform immunofluorescence and found that MMP-2 and MMP-9 were positively expressed in holoclone cells. Meroclone and paraclone cells even did not constitutively express MMP-2 and MMP-9 ( Figure 7b ).
Holoclone cells were trypsinized and grown in conditioned medium for 3 days. Then western blotting was used to compare MMPs expression in holoclone-derived cells and the parental Figure 6 . Holoclone cells showed CD133 þ phenotype and divided asymmetrically in vitro after trypsinized and passaged. (a) CD133 showed a consistent pattern of upregulated expression in holoclones when compared with paraclones and meroclones by immunofluorescence. (b) CD133 expression was different among holoclone (94 --97.6% in 7 cases), meroclone (1.7 --13.7% in 10 cases) and paraclone (0% in 6 cases) significantly (P ¼ 0.000). (c) Flowcytometry analysis in 48 h showed that the prevalence of CD133 þ cells in holoclone cells decreased from 97.6 to 53.5% after holoclone cells were trypsinized and passaged (first passage). With an additional two passages, the prevalence of CD133 þ population decreased to 25.4% (fourth passage).
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MDA-MB-231 cell. Although the parental cell expressed comparable levels of MMP-2 and MMP-9, the upregulated level of MMP-2 and MMP-9 presented in holoclone-derived cells (Figure 7c ). Taken together, the different development of VM patterns in the three clones partly related to the expression levels of MMP-2 and MMP-9.
DISCUSSION
Gene expression analyses have identified molecular subtypes that are refining our understanding of breast cancer biology. Tumors that neither express hormone receptors nor overexpress HER2 were defined as TN tumors. Recently, it has been reported that the poor outcomes seen in TN tumors were due to their biology, not resistance to chemotherapy. 20 The evolving concept of VM described the 'embryonic-like' ability of aggressive tumor cells to form vascular channels which correlated with poor prognosis. Therefore elucidating the biology of VM may help to develop novel cancer treatments in TN tumors.
In the present study, we have explored CD133 expression in 134 cases of invasive carcinoma. We found that the expression of CD133, a putative CSCs marker, correlated with two clinicopathological parameters (lymph node positive and high grade), which were traditionally associated with poor prognosis. Importantly, we observed that TN tumors had a higher proportion of CD133 þ cells, indicating that TN tumors have a greater stem cell-like phenotype. 23 Meantime we found that VM formation was significantly higher in the TN tumors. The VM structure can be formed by CD133 þ cells directly and breast cancer cells arranged in VM channels containing red blood cells showed apical/ endoluminal cell surface CD133 þ staining. However, the phenomena that VM channels didn't seem to be lined by CD133 þ cells was observed. Casual distribution of CD133 þ cancer cells was found in the tumor tissue and these CD133 þ cells were located in areas adjacent to VM, suggesting an association between CD133 þ cells and VM. The presence of the close relationship between CD133 expression and VM might be an important character of TN tumor and a key for TN tumor relapse and progression. MDA-MB-231 was selected by our group as it was TN breast cancer cell line and 25.4% CD133 þ cells present in bulk MDA-MB-231 population. Recently holoclone formation in culture at clonal densities was used to identify or isolate CSCs. 21, 22, 24 Several malignant epithelial cell lines had been reported to be comprized of three morphologically distinct clone types, designated paraclones, meroclones and holoclones. Our studies showed that cultured MDA-MB-231 cancer cells, when plated at clonal densities, showed marked clonal heterogeneity and developed a range of colony morphologies paralleling the holoclone, meroclone and paraclone morphologies. Holoclone cells were capable of forming more colonies on soft agar than meroclone cells and paraclone cells, suggesting that holoclone cells had a higher self-renew potential.
Strikingly, holoclone cells showed a consistent pattern of upregulated CD133 expression than paraclones and meroclones, suggesting CD133 þ cells could be CSCs population in TN breast cancer. Our results demonstrate that holoclone cells may derived from single CD133 þ cell that divided symmetrically. In addition, it was also indicated that CD133 þ holoclone cells had the differentiation ability and can divide asymmetrically and thus could give rise to CD133 þ /CD133 À populations that recapitulated the histological features of the parental cell line. The reverting to a bimodal CD133 expression pattern similar to that of the original cell line was observed when holoclone cells were passaged. Importantly, cells isolated from holoclones, unlike those from meroclones and paraclones, were able to form typical pipe-like structures (VM) within the 3D Matrigel medium. Our results suggested that holoclone cells might be critical in promoting VM formation of MDA-MB-231. Therefore it is conceivable that the subpopulation of CSCs or stem-like cells with CD133 þ phenotype existed in MDA-MB-231 is responsible for VM formation.
The staining of three different clones revealed that holoclones showed higher levels of VE-cadherin expression. VE-cadherin has a critical role as an intercellular adhesion and cascade signal transduction molecule in the formation of VM and might be involved in the initial signaling and regulation of the VM process. Hendrix et al. 25, 26 found the expression of VE-cadherin in highly aggressive melanoma tumor cells led to their ability to mimic endothelial cells and form VM in 3D culture. Recently it was reported that endothelial cells could be generated by the progeny of glioblastoma stem-like cells in vitro. 27 Our data showed that only holoclone cells under differentiation condition lost the shape of their morphology and showed VE-cadherin expression whereas neither meroclone nor paraclone showed detectable VEcadherin or CD31 expression. Therefore our results further demonstrated that holoclone cells with CSCs characteristic had the capacity of transdifferentiation and acquired endothelial cell phenotype and VE-cadherin expression, thus promoting VM.
Similarly, staining for MMP-2 and MMP-9, the major mediators for VM in malignant tumor, 28, 29 was also much stronger in holoclones than paraclone and meroclone. The MMP-9 and MMP-2 involved in tumor invasion and metastasis and the inhibition of their activity might be useful in preventing tumors from developing the vessels by way of VM. Other studies have indicated that MMP-2 and MMP-9 were necessary for the cleavage of laminin 5g2 chain into the g2 0 and g2x fragments and thus regulated the VM potential of highly aggressive melanoma cells. 30 The expression differences of MMP-2 and MMP-9 detected between holoclones, meroclones and paraclones in our studies were sufficiently marked and consistant, suggesting the upregulated pattern of MMP-2 and MMP-9 in holoclone cells might contribute to VM formation.
Therefore, taken together, the findings reported here indicated that (a) CD133 expression and VM had a close relationship with TN breast tumor. (b) A subpopulation of the cells within MDA-MB-231 cell lines with holoclone morphology showed CD133 þ phenotype and had a higher self-renew potential; (c) these cells were responsible for VM of bulk population of MDA-MB-231 in vitro and thus facilitated VM and (d) the expression of genes involved in VM such as VE-cadherin, MMP-2 and MMP-9 increased in CD133 þ cancer cell and it might due to the transdifferentiative ability of CSCs. In a word, we suggested that CSC subpopulation inside TN breast cancer was able to organize VM and a transdifferentiative capacity of CSCs might be needed. VM might represent an important survival mechanism contributing to the failure of currently available angiogenesis inhibitors to fully effect tumor eradication. Thus the use of anti-angiogenic drugs in combination with drugs acting on specific target of CSCs subpopulation opened of course interesting new therapeutic perspectives for the treatment of TN breast cancer.
MATERIALS AND METHODS
Cell culture
The breast cancer cell lines used in this study were MDA-MB-231, MCF-7 and T47D (from the American Type Culture Collection, Rockville, MD, USA). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA).
3D cultures
Tumor cells were mixture-seeded with Matrigel (Collaborative Biomedical, Bedford, MA, USA) to allow them to polymerize. The addition of regular medium was performed during the incubation. Cells were photographed using a phase contrast microscope (Nikon USA, Garden City, NY, USA).
Isolation of holoclones, meroclones and paraclones
Two methods were used to characterize the clonal composition of MDA-MB-231 cell line: low-density plating in 100 mm tissue culture dishes and 96-well plating by limiting dilution. For low-density plating, B8000 MDA-MB-231 cells were seeded in a 100 mm tissue culture dish to maintain the cell density between 50 and 200 cells per cm 2 . For plating by limited dilution, each well of a 96-well plate was seeded with 100 ml culture medium containing a calculated 10 MDA-MB-231 cells/ml. After 2 h, when the cells were attached, wells containing a single cell were marked; empty wells and wells containing more than one cell were excluded. Individual clones formed within 6 --7 days and were designated as holoclones, meroclones or paraclones based on their morphology. The colonies were grown to confluence for immunofluorescence or passaged for protein extraction and further propagation.
Soft agar colony formation assay
Soft agar colony formation assay was performed by seeding cells in a layer of 0.35% agar DMEM/FBS over a layer of 0.5% agar/DMEM/FBS. Additional complete media was added every 2 days to continuously supply growth supplements to the cells. Cultures were maintained in a humidified 37 1C incubator. On day 14 or day 21 after seeding, cells were fixed with pure ethanol containing 0.05% crystal violet and CFE quantified by light microscopy.
Flow cytometry analysis
After trypsinized, cells were fixed with 75% ethanol. Indirect labeling method was used to incubate primary antibody CD133 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and second antibody (Santa Cruz Biotechnology). Red fluorescence used PE (FL2 channel) and green fluorescence used fluorescein isothiocyanate (FL1 channel). C6 flow cytometry (Accuri, Ann Arbor, MI, USA) was used for determination.
Immunofluorescence
Cells were fixed in absolute methanol at À20 1C for 20 min, blocked in 5% normal goat serum and incubated with primary antibodies. Primary antibodies against the proteins CD133 (Santa Cruz Biotechnology), VE-cadherin (Santa Cruz Biotechnology), MMP-2 (Santa Cruz Biotechno-logy) and MMP-9 (Lab Vision, Kalamazoo, MI, USA) were followed by secondary antibodies. The fluorescein isothiocyanate-conjugated mouse and rabbit immunoglobulin G antibody (Santa Cruz Biotechnology) were used as labels for immunofluorescence assay. After immunolabeling, cells were washed, stained with DAPI (Sigma, St Louis, MO, USA), mounted and then viewed with fluorescent microscopy (Nikon) and analyzed as maximum projections. Values reported represent the average of 100 cells in each of two independent experiments.
Western blot analysis
The whole cell lysates were resolved by way of sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). Blots were blocked and incubated with the monoclonal antibody (MMP-2 and MMP-9, 1:500), followed by incubation with a secondary antibody (1:2000; Santa Cruz Biotechnology). Blots were developed using an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). 
Immunohistochemical and histochemical double-staining methods
Tissue sections (5 mm) were deparaffinized and hydrated utilizing standard procedures. Immunostaining was performed using the super-sensitivity S-P IHC kit. Anti-CD133 antibody (Santa Cruz Biotechnology) and anti-CD31 antibody (Beijing Zhongshan Biotechnology Limited Company, Peking, China) primary antibody was applied to the sections at a dilution ratio of 1:100 and 1:40, respectively. Antigen retrieval has been done for both antibodies. The staining systems used in this study were PicTure PV6000 (Zhongshan Chemical Co., Beijing, China) and Elivision Plus (Zhongshan Chemical Co.). Finally, the sections were counterstained with hematoxylin or PAS. Phosphate-buffered saline was used in place of the primary antibodies for the negative control.
